Securing Cell Size Homogenization Technology
Expanding Patent Portfolio in Asia

Kolon Life Science has secured a manufacturing-related patent for TG-C, a cell and gene therapy for osteoarthritis currently being developed by its affiliate Kolon TissueGene, in Singapore.


Kolon Life Science Headquarters Building Exterior. Kolon Life Science

Kolon Life Science Headquarters Building Exterior. Kolon Life Science

View original image

Kolon Life Science announced on the 17th that its patent for a “pharmaceutical composition for the prevention or treatment of osteoarthritis” has been approved for registration in Singapore. This patent includes both the composition and manufacturing methods related to the technology that enables the stable acquisition of cells of a certain size during the manufacturing process of TG-C.


TG-C is a cell and gene therapy injected into the knee joint cavity. It is being developed using a method that involves mixing allogeneic cartilage-derived chondrocytes with genetically modified cells into which the TGF-β1 gene has been introduced.


This patented technology includes a manufacturing process that removes cell aggregates formed during cell culture and secures cells within a specific size range. Kolon Life Science explained that, through this technology, it has secured the rights to consistently control cell characteristics during TG-C production.


This patent has already been registered in the United States, Korea, Japan, and Australia, and applications are underway in countries such as China and Canada. Kolon Life Science plans to continue securing rights for the commercialization of TG-C across Asia based on the acquisition of this Singaporean patent.


Lee Hankook, CEO of Kolon Life Science, said, "Our technological competitiveness in stably managing cell quality during TG-C manufacturing is being recognized internationally," adding, "We will continue preparing for global commercialization."



Kolon TissueGene, the developer of TG-C, is scheduled to announce topline results from its Phase 3 clinical trial in the United States in July. The company will then proceed with preparations for a product approval application to the U.S. Food and Drug Administration (FDA).


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing